On December 10, 2015, the ninth participant was treated in our Israeli study of MDMA-assisted psychotherapy for PTSD. The tenth and final participant was enrolled on December 16. Led by Principal Investigator Moshe Kotler, M.D., this Phase 2 study will treat 10 subjects with chronic, treatment-resistant PTSD from any cause. “We are in the final stages of the Phase 2 research in Israel, having worked over the last few years with a variety of participants, their stories, feelings, body experiences, and the traumas that these reflect,” reports co-therapist Keren Tzarfaty, Ph.D. “As these intense processes unfold and old layers melt, we have been witnessing new seeds of healing and growth, love and hope, seeds of wholeness.” Once the final treatments and evaluations are complete, we will gather the data for inclusion in an international meta-analysis of the safety and efficacy of MDMA-assisted psychotherapy for the treatment of PTSD. olled on December 16. Led by Principal Investigator Moshe Kotler, M.D., this Phase 2 study will treat 10 subjects with chronic, treatment-resistant PTSD from any cause. “We are in the final stages of the Phase 2 research in Israel, having worked over the last few years with a variety of participants, their stories, feelings, body experiences, and the traumas that these reflect,” reports co-therapist Keren Tzarfaty, Ph.D. “As these intense processes unfold and old layers melt, we have been witnessing new seeds of healing and growth, love and hope, seeds of wholeness.” Once the final treatments and evaluations are complete, we will gather the data for inclusion in an international meta-analysis of the safety and efficacy of MDMA-assisted psychotherapy for the treatment of PTSD.
